A Study of a New Leishmania Vaccine Candidate ChAd63-KH
NCT02894008
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
24
Enrollment
OTHER
Sponsor class
Conditions
Leishmaniasis, Cutaneous
Interventions
DRUG:
ChAd63-KH
Sponsor
University of York
Collaborators
[object Object]